Ripretinib
Qinlock
Sources
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f18e462-03dd-4296-a02a-a0577e3ee78d
Median PFS (months) (95% CI) 6.3 (4.6, 6.9) 1.0 (0.9, 1.7) Hazard ratio 0.15 ... Overall Response Rate (%) 9 0 ... Median OS (months) 15.1 (12.3, 15.1) 6.6 (4.1, 11.6) Hazard ratio 0.36
Qinlock USPI section 1 and section 14, Table 6, INVICTUS (NCT03353753)
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/35947817/
median PFS (ITT) was 8.0 and 8.3 months, respectively (hazard ratio, 1.05; 95% CI, 0.82 to 1.33; nominal P = .72) ... Median PFS for ripretinib and sunitinib (KIT exon 11 ITT) was 8.3 and 7.0 months ... Objective response rate was higher for ripretinib versus sunitinib in the KIT exon 11 ITT population (23.9% v 14.6%, nominal P = .03) ... grade 3/4 treatment-emergent adverse events (41.3% v 65.6%
Bauer S et al. J Clin Oncol 2022;40:3918-3928, PMID 35947817, abstract
publication, as of 2026-11-07
https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.TPS848
pts harboring primary KIT exon 11 mutations with secondary resistance mutations exclusively in KIT exons 17/18 derived PFS benefit with ripretinib vs sunitinib (median, 14.2 vs 1.5 months; HR, 0.22; 95% CI, 0.11 to 0.44; nominal P <0.0001; Heinrich MC et al. Nat Med. 2024) ... A total of 54 pts will be randomized (2:1)
J Clin Oncol 43(4_suppl) TPS848 (2025), INSIGHT design and INTRIGUE exploratory ctDNA citation
publication, as of 2026-11-07
https://link.springer.com/article/10.1245/s10434-024-16853-x
patients with primary KIT exon 11 and secondary exon 13/14 mutations detected in ctDNA had significantly improved outcomes when treated with sunitinib (median PFS 15.0 vs. 4.0 months; nominal p = 0.0005)
Annals of Surgical Oncology, INSIGHT trial article (2025)
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03353753
A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03673501
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05734105
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib
ClinicalTrials.gov API v2 record, retrieved 2026-11-07